Effects of Broncasma Berna on chronic sinusitis and nasal allergy.
Broncasma Berna is a polyvalent antigen vaccine containing eight types of bacteria or their autolysates which are commonly detected during infections of the upper respiratory tract and formed in clusters in the nasal and sinal cavities. This agent was administered to chronic sinusitis and nasal allergy patients; judgment of therapeutic effectiveness based on an independently developed scoring system showed the following results: markedly effective 2.5%, effective 42.5%, slightly effective 52.5% and ineffective 2.5%. No notable side-effects were observed. Although more study is required on such points as long term administration, posology, and application method especially Broncasma Berna aerosol nasal spray method, based on this study we can confirm that if the patient group is selected in a similar manner, the above reported therapeutic results can certainly be obtained. Broncasma Berna because of its non-specific desensitization effect has value as the drug of preference in treating nasal allergy cases where a specific antigen can not be found, and chronic sinusitis with a convoluted chronic course, especially where the involvement of infectious allergy is suspected.
D000293:Adolescent; D000328:Adult; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D012852:Sinusitis / Q000188:drug therapy*
D001428:Bacterial Vaccines; C036563:broncasma berna